Arrowhead presents preclinical data on new ARO-INHBE

Arrowhead Pharmaceuticals announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association, ADA, 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next generation therapies to address obesity and metabolic diseases. Further, Arrowhead’s preclinical research suggests that INHBE knockdown may potentially lead to a suppression in body weight gain, loss of fat mass, and preservation of lean mass. Arrowhead plans to file for regulatory clearance in late 2024 to begin clinical studies of ARO-INHBE.